These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 20633737)
1. Ecchymoses as an adverse effect of fluvoxamine treatment in an adolescent girl. Vlatka BM; Branka AM; Branimir M Gen Hosp Psychiatry; 2010; 32(4):e9-e10. PubMed ID: 20633737 [No Abstract] [Full Text] [Related]
2. Disinhibition as a side effect of treatment with fluvoxamine in pediatric patients with obsessive-compulsive disorder. Harris E; Eng HY; Kowatch R; Delgado SV; Saldaña SN J Child Adolesc Psychopharmacol; 2010 Aug; 20(4):347-53. PubMed ID: 20807074 [TBL] [Abstract][Full Text] [Related]
3. Euprolactinemic gynecomastia and galactorrhea with risperidone-fluvoxamine combination. Pratheesh PJ; Praharaj SK; Srivastava A Psychopharmacol Bull; 2011; 44(1):70-3. PubMed ID: 22506441 [TBL] [Abstract][Full Text] [Related]
4. Photosensitivity reaction associated with selective serotonin re-uptake inhibitors: possible cross-sensitivity? Cheng YC; Huang MC Psychiatry Clin Neurosci; 2014 Mar; 68(3):244. PubMed ID: 24895743 [No Abstract] [Full Text] [Related]
5. Extended-release fluvoxamine (Luvox CR). Med Lett Drugs Ther; 2008 Jun; 50(1289):50-1. PubMed ID: 18583947 [No Abstract] [Full Text] [Related]
6. Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial. Goodman WK; Kozak MJ; Liebowitz M; White KL Int Clin Psychopharmacol; 1996 Mar; 11(1):21-9. PubMed ID: 8732310 [TBL] [Abstract][Full Text] [Related]
7. Fluvoxamine open-label treatment of adolescent inpatients with obsessive-compulsive disorder or depression. Apter A; Ratzoni G; King RA; Weizman A; Iancu I; Binder M; Riddle MA J Am Acad Child Adolesc Psychiatry; 1994; 33(3):342-8. PubMed ID: 8169178 [TBL] [Abstract][Full Text] [Related]
8. Antidepressant-induced hypomania in obsessive-compulsive disorder. Rihmer Z; Barsi J; Belsõ N; Pestality P; György S Int Clin Psychopharmacol; 1996 Sep; 11(3):203-5. PubMed ID: 8923100 [TBL] [Abstract][Full Text] [Related]
9. Clinical impact of fluvoxamine-mediated long QTU syndrome. Nia AM; Dahlem KM; Gassanov N; Hungerbühler H; Fuhr U; Er F Eur J Clin Pharmacol; 2012 Jan; 68(1):109-11. PubMed ID: 21713517 [No Abstract] [Full Text] [Related]
10. Fluvoxamine-Associated Galactorrhea: A Case Report. Chakladar A; Singh J; Tak NK; Patra BN; Sagar R J Clin Psychopharmacol; 2020; 40(1):101-102. PubMed ID: 31804454 [No Abstract] [Full Text] [Related]
11. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. Hollander E; Koran LM; Goodman WK; Greist JH; Ninan PT; Yang H; Li D; Barbato LM J Clin Psychiatry; 2003 Jun; 64(6):640-7. PubMed ID: 12823077 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study. Mundo E; Bianchi L; Bellodi L J Clin Psychopharmacol; 1997 Aug; 17(4):267-71. PubMed ID: 9241005 [TBL] [Abstract][Full Text] [Related]
13. [Obsessive-compulsive disorder, frontostriatal system and the effect of the serotonergic system]. Baving L; Schmidt MH Z Kinder Jugendpsychiatr Psychother; 2000 Feb; 28(1):35-44. PubMed ID: 10746297 [TBL] [Abstract][Full Text] [Related]
14. Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder. Heidari M; Zarei M; Hosseini SM; Taghvaei R; Maleki H; Tabrizi M; Fallah J; Akhondzadeh S Int Clin Psychopharmacol; 2014 Nov; 29(6):344-50. PubMed ID: 24850229 [TBL] [Abstract][Full Text] [Related]